Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ido Wolf

Showing results (71-80 of 128) with videos related to

Pageof 13
Sort By:
The Oncologist|December 10, 2024
Squamous cell carcinoma arising in chronically damaged skin (Marjolin's Ulcer): still an unmet need in the era of immunotherapyMor Miodovnik, Yardenna Dolev, Roni Buchen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2019
Ligand-binding Domain-activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer CellsLotem Zinger, Keren Merenbakh-Lamin, Anat Klein, et al.
World Neurosurgery|June 23, 2019
Role of Klotho Protein in Tumor Genesis, Cancer Progression, and Prognosis in Patients with High-Grade GliomaNaama Peshes-Yeloz, Lior Ungar, Anton Wohl, et al.
Breast Cancer Research and Treatment|November 2, 2011
Epigenetic silencing of the tumor suppressor klotho in human breast cancerTami Rubinek, Michal Shulman, Shira Israeli, et al.
American Journal of Clinical Oncology|July 1, 2009
Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patientsShani Paluch-Shimon, Noa Ben-Baruch, Ido Wolf, et al.
Cancers|June 10, 2023
Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?Yossi Maman, Yaacov Goykhman, Oz Yakir, et al.
The Oncologist|July 14, 2020
Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian CancerTamar Safra, Barliz Waissengrin, Talya Levy, et al.
Cancer Research|August 4, 2006
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancerIdo Wolf, James O'Kelly, Tamar Rubinek, et al.
Science Translational Medicine|May 17, 2013
Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertilityLital Kalich-Philosoph, Hadassa Roness, Alon Carmely, et al.
Breast Cancer Research and Treatment|January 31, 2014
Association between variants of 5-hydroxytryptamine receptor 3C (HTR3C) and chemotherapy-induced symptoms in women receiving adjuvant treatment for breast cancerDorit Pud, Gil Har-Zahav, Yael Laitman, et al.
Pageof 13

Showing results (71-80 of 128) with videos related to

Sort By:
Pageof 13
The Oncologist|December 10, 2024
Squamous cell carcinoma arising in chronically damaged skin (Marjolin's Ulcer): still an unmet need in the era of immunotherapyMor Miodovnik, Yardenna Dolev, Roni Buchen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2019
Ligand-binding Domain-activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer CellsLotem Zinger, Keren Merenbakh-Lamin, Anat Klein, et al.
World Neurosurgery|June 23, 2019
Role of Klotho Protein in Tumor Genesis, Cancer Progression, and Prognosis in Patients with High-Grade GliomaNaama Peshes-Yeloz, Lior Ungar, Anton Wohl, et al.
Breast Cancer Research and Treatment|November 2, 2011
Epigenetic silencing of the tumor suppressor klotho in human breast cancerTami Rubinek, Michal Shulman, Shira Israeli, et al.
American Journal of Clinical Oncology|July 1, 2009
Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patientsShani Paluch-Shimon, Noa Ben-Baruch, Ido Wolf, et al.
Cancers|June 10, 2023
Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?Yossi Maman, Yaacov Goykhman, Oz Yakir, et al.
The Oncologist|July 14, 2020
Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian CancerTamar Safra, Barliz Waissengrin, Talya Levy, et al.
Cancer Research|August 4, 2006
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancerIdo Wolf, James O'Kelly, Tamar Rubinek, et al.
Science Translational Medicine|May 17, 2013
Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertilityLital Kalich-Philosoph, Hadassa Roness, Alon Carmely, et al.
Breast Cancer Research and Treatment|January 31, 2014
Association between variants of 5-hydroxytryptamine receptor 3C (HTR3C) and chemotherapy-induced symptoms in women receiving adjuvant treatment for breast cancerDorit Pud, Gil Har-Zahav, Yael Laitman, et al.
Pageof 13